Sorrento’s Partner Mabpharm Files For Infliximab In China
Sorrento Plans US Filing For Infliximab ‘Biobetter’ In 2020
• By Akriti Seth
Following Mabpharm’s filing for an infliximab biosimilar in China, Sorrento plans to file for a ‘biobetter’ in the US in 2020 • Source: Shutterstock 
